A randomized, exploratory, open-label 48-week trial with a 2-week pre-treatment phase to investigate the Pharmacokinetics, safety, tolerability and antiviral activity of Etravirine (ETR) in combination with Ritonavir-boosted Atazanavir (ATV/rtv) and 1 NRTI in treatment-experienced HIV-1 infected subjects